Archive

What perimenopause is at the biological level, why the window of hormone therapy initiation matters for both cardiovascular and bone density outcomes, how bioidentical estradiol, progesterone, and testosterone address distinct dimensions of the transition, and how sleep peptides, kisspeptin, GLP-1 therapy, and growth hormone peptides complete a comprehensive perimenopausal protocol.

What KPV is, how its inhibition of NF-kB prevents inflammatory gene expression at the transcriptional level rather than managing inflammation after it is already underway, why its gut applications are distinct from its systemic effects, and what role it plays in the Wolverine 2 and Klow combination stacks.

How sermorelin and CJC-1295/Ipamorelin stimulate growth hormone through the same upstream GHRH mechanism but with meaningfully different half-lives, pulse characteristics, and potency, who is best suited for each based on goals and clinical profile, and where the new Sermorelin/Ipamorelin combination fits in the landscape.

Why type 2 diabetes is an insulin resistance problem rather than a glucose problem, how GLP-1 therapy, MOTS-C, NAD+, growth hormone peptides, and thyroid optimization each address distinct upstream mechanisms, and what realistic outcomes look like when the full optimization toolkit is applied to this population

What TB-500 is, how its actin-based cellular migration mechanism produces systemic repair effects that BPC-157’s local angiogenic mechanism does not, why the combination addresses tissue repair from both local and systemic dimensions simultaneously, and who benefits most from TB-500’s broader distribution pattern.